Stock Events

Stock Events

Lytix Biopharma AS 

€0.7300
0
-€0.01-1.62% Friday 17:47

Statistics

Day High
0.756
Day Low
0.73
52W High
0.966
52W Low
0.311
Volume
-
Avg. Volume
-
Mkt Cap
56.14M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Jun 17
€0.76
Jul 16
€0.71
Jun 15
€0.53
Jun 14
€0.49
Jun 13
€0.49
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Financials

-860.49%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
951,045.51Revenue
-8.18MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6BG.STU. It's not an investment recommendation.
Equinor ASA
2
EQNR.OL
MPC Container Ships ASA
2
MPCC.OL
Var Energi ASA
2
VAR.OL
Nykode Therapeutics AS
2
NYKD.OL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap370.89B
Merck & Co., Inc. develops oncology drugs that directly compete with Lytix's cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol-Myers Squibb Company offers a range of immunotherapies in oncology, overlapping with Lytix's product pipeline.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a leader in oncology, with a broad portfolio that competes in the same therapeutic areas as Lytix.
Pfizer
PFE
Mkt Cap162.16B
Pfizer Inc. has extensive investments in cancer treatment development, competing in the same market as Lytix Biopharma.
Novartis
NVS
Mkt Cap292.35B
Novartis AG focuses on innovative medicines in oncology, directly competing with Lytix's cancer therapies.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a strong focus on oncology, particularly in developing new cancer treatments that compete with Lytix.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. develops therapies for various cancer types, competing with Lytix's research and development in oncology.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is involved in the development of oncology drugs, which places them in direct competition with Lytix.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. works on innovative cancer treatments, competing in the same niche as Lytix.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical division, develops cancer therapies that compete with Lytix's products.

About

Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
Show more...
CEO
Oystein Rekdal
Employees
14
Country
Other
ISIN
NO0010405780
WKN
000A3CSAK

Listings

STU
DE
6BG.STU
OL
NO
LYTIX.OL
F
DE
6BG.F

0 Comments

Share your thoughts

FAQ

What is Lytix Biopharma AS stock price today?▼
The current price of 6BG.STU is €0.73 EUR — it has decreased by -1.62% in the past 24 hours. Watch Lytix Biopharma AS stock price performance more closely on the chart.
What is Lytix Biopharma AS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Lytix Biopharma AS stocks are traded under the ticker 6BG.STU.
Is Lytix Biopharma AS stock price growing?▼
6BG.STU stock has fallen by -1.35% compared to the previous week, the month change is a -0.82% fall, over the last year Lytix Biopharma AS has showed a +16.99% increase.
What is Lytix Biopharma AS market cap?▼
Today Lytix Biopharma AS has the market capitalization of 56.14M
What is Lytix Biopharma AS revenue for the last year?▼
Lytix Biopharma AS revenue for the last year amounts to 951,045.51 EUR.
What is Lytix Biopharma AS net income for the last year?▼
6BG.STU net income for the last year is -8.18M EUR.
Does Lytix Biopharma AS pay dividends?▼
Yes, 6BG.STU dividends are paid annual. The last dividend per share was 0.76 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Lytix Biopharma AS have?▼
As of September 07, 2026, the company has 14 employees.
In which sector is Lytix Biopharma AS located?▼
Lytix Biopharma AS operates in the Health & Wellness sector.
When did Lytix Biopharma AS complete a stock split?▼
Lytix Biopharma AS has not had any recent stock splits.
Where is Lytix Biopharma AS headquartered?▼
Lytix Biopharma AS is headquartered in Oslo, Other.